2 Canadian Pot Stocks Trading Below $1

The Green Organic Dutchman and Auxly Cannabis are high growth penny stocks in the cannabis space. Is it time to add them to your portfolio?

Female scientist in a hemp field checking plants and flowers, alternative herbal medicine concept

Image source: Getty Images

The bear market in the cannabis space has extended to November 2019. Several investors have lost considerable value after the market peaked in October last year.

A few stocks have lost close to 90% in market value and are trading at multi-year lows. There are varied opinions regarding the end of the current bear run, as few believe pot stocks to be overvalued even at current levels.

Here we look at two Canadian penny stocks in the marijuana space. The two companies are The Green Organic Dutchman (TSX:TGOD) and Auxly Cannabis Group (TSXV:XLY). While TGOD is trading at $0.95, Auxly Cannabis is trading at $0.69.

Penny stocks are generally micro-cap stocks that have low stock prices (generally below $1) but with the potential to gain exponentially. We know that the cannabis space continues to grow as several countries are legalizing recreational and medical marijuana products.

The Green Organic Dutchman

TGOD went public on May 4, 2018, and closed trading at $3.95 that day. The stock rose to $8.25 by September 2018 and has since lost 88% in market value.

TGOD investors were impacted after it lost 45% in October 2019 after the company announced it is struggling to raise debt capital.

The stock also fell this month after lower than expected revenue figures in the third quarter of 2019. However, TGOD announced it has secured debt funding of $103 million to finance the construction of its Valleyfield and Ancaster facilities.

Several financial institutions are wary of lending to cannabis companies, as these products are still illegal at the federal level in the U.S.

This may soon change, however, as the U.S. House of Representatives passed a bill legalizing marijuana at the federal level. The bill still has to be approved by the Senate, which might take longer than expected.

TGOD stock is currently valued at $262 million or 11.2 times forward sales. Analysts expect company sales to rise by 1,100% to $23.33 million in 2019 and 500% to $139.15 million in 2020.

There is a good chance that TGOD will miss these estimates at least in the December quarter given the slow rollout of retail stores across Canadian provinces. Analysts tracking TGOD have a 12-month target price of $3.24 for the stock, 241% higher than the current trading price.

Auxly Cannabis

Auxly went public on January 29, 2015, and closed trading at $0.02 that day. The stock rose by a staggering 12,500% to $2.53 by January 2018 and has since lost 73% in market value. Despite the decline in the last two years, however, Auxly stock has returned over 3,000% since the IPO.

Auxly has estimated the marijuana market in Canada to expand from $6 billion in 2019 to $11 billion in 2025. Looking at the expanding addressable market, Auxly has increased its supply to 100,000 kilograms per annum. This includes production from wholly-owned subsidiaries, joint ventures, and offtake agreements.

Auxly is excited about its portfolio of products, which will accelerate revenue growth across domestic and international markets.

Auxly stock is currently valued at $433.5 million, or 74 times forward sales. Analysts expect company sales to rise by 939.6% to $5.85 million in 2019 and accelerate to 3051% to $184.44 million in 2020. We can see that Auxly’s astonishing valuation is supported by an equally robust growth rate.

Analysts tracking Auxly have a 12-month target price of $1.23 for the stock which is 78% higher than the current trading price.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends Auxly Cannabis Group. Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »